Get started

Bullishchart

Bullish Charts - Huge Earrings BeatDURECT Corporation, a biopharmaceutical company, researches and develops medicines based on its epigenetic regulator and pharmaceutical programs. The company offers ALZET product line that consists of osmotic pumps and accessories used for experimental research in mice, rats, and other laboratory animals; and a range of biodegradable polymers for pharmaceutical and medical device clients for use as raw materials in their products under the LACTEL brand. Its product pipeline consists of multiple investigational drug candidates in development, such as DUR-928, an endogenous, orally bioavailable small molecule that is in Phase I and II development stage to play a regulatory role in lipid homeostasis, inflammation, and cell survival. The company's oral and injectable delivery technologies are designed to enable new indications and enhanced attributes for small-molecule and biologic drugs, including POSIMIR, an investigational analgesic product intended to deliver bupivacaine to provide up to 3 days of pain relief after surgery. DURECT Corporation markets and sells its ALZET and LACTEL product lines through direct sales force in the United States, as well as through a network of distributors in Japan, Europe, and internationally. The company has strategic collaboration and other agreements with Virginia Commonwealth University Intellectual Property Foundation; Indivior UK Ltd.; Santen Pharmaceutical Co., Ltd.; Sandoz AG; and Zogenix, Inc. DURECT Corporation was founded in 1998 and is headquartered in Cupertino, California. This morning Durect reported earrings that blew away Wall Street Estimates. Q2 EPS $0.07 Up From $(0.04) YoY, Sales $25 Million Beat $11.48 Million Estimate Sales more than doubled estimates. Daily Chart is Bullish Indicators are rising, Bullish Long! DISCLAIMER The Content herein is for informational purposes only, you should not construe any such information or other material as legal, tax, investment, financial, or other advice.
NASDAQ:DRRXLong
by HotCharts
Bullish Charts - Oversold & Undervalued Pfizer Inc. develops, manufactures, and sells healthcare products worldwide. It offers medicines and vaccines in various therapeutic areas, including internal medicine, such as cardiovascular metabolic and pain under the Eliquis, Chantix/Champix, and Premarin family brands; oncology, such as biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Sutent, Xtandi, Xalkori, Inlyta, Braftovi + Mektovi brands; and sterile injectable and anti-infective medicines under the Sulperazon, Medrol, Vfend, and Zithromax brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, and tick-borne encephalitis under the Prevnar 13/Prevenar 13 (pediatric/adult), FSME-IMMUN, Nimenrix, and Trumenba brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, and Eucrisa brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, Genotropin, and Refacto AF/Xyntha brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration and/or co-promotion agreements with Bristol-Myers Squibb Company and Astellas Pharma US, Inc.; licensing agreement with Akcea Therapeutics, Inc; strategic alliance with Verily Life Sciences LLC; collaboration agreement with Merck KGaA; clinical trial collaboration and supply agreement with IDEAYA Biosciences, Inc.; material transfer and collaboration agreement with BioNTech SE to co-develop COVID-19 vaccine; clinical supply collaboration Jiangsu Alphamab Biopharmaceuticals Co., Ltd; and collaboration with Valneva SE to develop and commercialize Valneva's Lyme disease vaccine candidate VLA15. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York. Pfizer is one of the most unappreciated stocks in its industry and the low price shows. Recently, institutions have taken notice and started upgrading the stock with price targets north of $40.00 a share. Pfizer is also working on a COVID-19 vaccine and could be months ahead of other companies. On the daily chart, the stock is sitting is sitting and bouncing off support around $33.00. It's ready for a move up any day. Long!
NYSE:PFELong
by HotCharts
Bullish Charts - Ready to Explode HigherOrigin Agritech Limited, through its subsidiaries, operates an agricultural biotechnology and an e-commerce platform primarily in the People's Republic of China. The company engages in crop seed breeding and genetic improvement activities. It develops, produces, and distributes hybrid crop seeds, as well as hybrid seed technology. The company also operates an e-commerce platform, which delivers agricultural products comprising agricultural seed products, other agricultural inputs, foods, household products, and other consumer products to farmers through online and mobile ordering. Origin Agritech Limited was founded in 1997 and is headquartered in Beijing, China. From the looks of what I read, SEED is could have approval any day to start growing its biotech corn in China. Looking for a pop soon. Target - $9.00 to $10 Long
NASDAQ:SEEDLong
by HotCharts
REN/BTC potential ending correction and starting new cycle REN / BTC (Binance) - I'm sending you the Christmas Forecast as a selection of dozens of charts I've gone through today. Even though some altcoins record smaller impulses, I I do not want to jump into them immediately for one simple reason ... Dominance has barely moved since yesterday and there is no sign of decline so it can only be retracements within the current Altcoin correction. However, I like REN because it is a fundamentally decent project that has seen a decent uptrend in a short time since the listing and has since consolidated in the triangle. The volume decreases towards the apex, which prepares the graph for a larger impulse. The RSI at 1D in the neutral zone below 40, the MACD and the Histogram twist around the equilibrium point currently slightly to buy, ready for a larger impulse. No later than 31.12. there will be a breakout point from the triangle and I find it illogical to break down such a structure. 1D chart: All the more I like the structure of the fact that in the apex of a huge cyclic triangle we see a PRZ for a potential BULLISH GARTLEY pattern with a PRZ between 422sat and 400sat, where we observe precise AB = CD, 0.886XA retracement and 1.41BC projection. Harmonic Patterns We do not trade over limit buys, although I personally like the primary trend line at the bottom of the PRZ, which keeps REN from the bottom of the uptrend. To enter after testing all PRZ points ( I expect even lower leg down, or after break from resistance trend).  Set alerts because a fomo may occur after a breakout. SL according to strategy, possibly under point X (359sat). The targets of the pattern / middleterm exit zone are shown in the chart, I do not exclude that if properly supported by the bulls, it can kick off another beautiful UP run. 12h graph: I wish everyone a peaceful Christmas, peace with family and loved ones and good taste at dinner. :)
Long
by Tradify_Seb
Cup and Handle-The cup and handle is a bullish continuation pattern used to find buying opportunities in the market. -The pattern is composed of two sections; the cup and the handle. -The cup should be rounded and just under two thirds the height of the initial move. -Handle should not pull back more than the right side of the cup and traders can enter on a trend line break of the handle. -Take profit is measured using the base of the cup to the breakout point and extending this measurement above the breakout to the upside.
COINBASE:BTCUSDEducation
by CryptoC77
9